Literature DB >> 7692978

Identification of a brain-specific human cerebrospinal fluid glycoprotein, beta-trace protein.

M G Harrington1, R Aebersold, B M Martin, C R Merril, L Hood.   

Abstract

A prominent human cerebrospinal fluid (CSF) protein, P5, identified at mass 19-24 kDa and charge 5.5, by two-dimensional electrophoresis (2DE) and silver staining, has been previously demonstrated to be reduced in quantity in the CSF of patients with multiple sclerosis and schizophrenia. We report the purification and partial amino acid sequences from five tryptic fragments of P5. These sequences are not those of any known sequence in the Protein Identification Resource (PIR release 31) database. Synthetic peptides from two of the sequences were used to raise rabbit polyclonal antibodies. These antibodies detected P5 on 2DE blots of normal CSF proteins and other proteins of the same mass with a charge distribution between 5.17-8.5. These proteins comprise 5-10% of the total CSF protein and their mass, charge, abundance and predominance in CSF over plasma are consistent with a protein that had been initially characterized with antibodies, beta-trace protein. Glycosidase studies confirm that most of these proteins are due to sialic acid modifications that are N-linked to an 18 kDa protein, but other charge and mass variations also exist. 2DE blots of 26 types of human tissue and body fluid were immunostained. Of these, anti-P5 serum detected proteins of the same mass and charge as beta-trace protein only in brain samples. Proteins of different mass and charge from beta-trace protein were clearly immunostained in samples of eight tissues.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692978

Source DB:  PubMed          Journal:  Appl Theor Electrophor        ISSN: 0954-6642


  8 in total

1.  Mass spectrometric analysis of rat cerebrospinal fluid proteins following exposure to the neurotoxicant carbonyl sulfide.

Authors:  O Lardinois; P J Kirby; D L Morgan; R C Sills; K B Tomer; L J Deterding
Journal:  Rapid Commun Mass Spectrom       Date:  2014-12-15       Impact factor: 2.419

Review 2.  Methods of assessing renal function.

Authors:  Guido Filler; Abeer Yasin; Mara Medeiros
Journal:  Pediatr Nephrol       Date:  2013-02-17       Impact factor: 3.714

Review 3.  Update on Estimation of Kidney Function in Diabetic Kidney Disease.

Authors:  Petter Bjornstad; David Z Cherney; David M Maahs
Journal:  Curr Diab Rep       Date:  2015-09       Impact factor: 4.810

4.  Lipocalin-type prostaglandin D synthase scavenges biliverdin in the cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage.

Authors:  Takashi Inui; Mitsuhito Mase; Ryoko Shirota; Mariko Nagashima; Tetsuya Okada; Yoshihiro Urade
Journal:  J Cereb Blood Flow Metab       Date:  2014-07-09       Impact factor: 6.200

5.  Beta-trace Protein as a new non-invasive immunological Marker for Quinolinic Acid-induced impaired Blood-Brain Barrier Integrity.

Authors:  Andreas Baranyi; Omid Amouzadeh-Ghadikolai; Dirk von Lewinski; Robert J Breitenecker; Tatjana Stojakovic; Winfried März; Christoph Robier; Hans-Bernd Rothenhäusler; Harald Mangge; Andreas Meinitzer
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

6.  The morphology and biochemistry of nanostructures provide evidence for synthesis and signaling functions in human cerebrospinal fluid.

Authors:  Michael G Harrington; Alfred N Fonteh; Elena Oborina; Patricia Liao; Robert P Cowan; Gordon McComb; Jesus N Chavez; John Rush; Roger G Biringer; Andreas F Hühmer
Journal:  Cerebrospinal Fluid Res       Date:  2009-09-07

Review 7.  Resolution of Inflammation: What Controls Its Onset?

Authors:  Michelle A Sugimoto; Lirlândia P Sousa; Vanessa Pinho; Mauro Perretti; Mauro M Teixeira
Journal:  Front Immunol       Date:  2016-04-26       Impact factor: 7.561

8.  Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-overuse headache.

Authors:  Lanfranco Pellesi; Elisa Bellei; Simona Guerzoni; Maria Michela Cainazzo; Carlo Baraldi; Emanuela Monari; Luigi Alberto Pini
Journal:  BMC Neurol       Date:  2019-10-17       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.